| 000 | 01746 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250517131102.0 | ||
| 264 | 0 | _c20171214 | |
| 008 | 201712s 0 0 eng d | ||
| 022 | _a1573-0646 | ||
| 024 | 7 |
_a10.1007/s10637-016-0414-z _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLundberg, Alycen P | |
| 245 | 0 | 0 |
_aPharmacokinetics and derivation of an anticancer dosing regimen for the novel anti-cancer agent isobutyl-deoxynyboquinone (IB-DNQ), a NQO1 bioactivatable molecule, in the domestic felid species. _h[electronic resource] |
| 260 |
_bInvestigational new drugs _c04 2017 |
||
| 300 |
_a134-144 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _a8-Hydroxy-2'-Deoxyguanosine |
| 650 | 0 | 4 | _aA549 Cells |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 |
_aCarcinoma, Squamous Cell _xblood |
| 650 | 0 | 4 | _aCats |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCell Survival _xdrug effects |
| 650 | 0 | 4 |
_aDeoxyguanosine _xanalogs & derivatives |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHEK293 Cells |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMouth Neoplasms _xblood |
| 650 | 0 | 4 |
_aNAD(P)H Dehydrogenase (Quinone) _xmetabolism |
| 650 | 0 | 4 |
_aQuinones _xadverse effects |
| 700 | 1 | _aFrancis, Joshua M | |
| 700 | 1 | _aPajak, Malgorzata | |
| 700 | 1 | _aParkinson, Elizabeth I | |
| 700 | 1 | _aWycislo, Kathryn L | |
| 700 | 1 | _aRosol, Thomas J | |
| 700 | 1 | _aBrown, Megan E | |
| 700 | 1 | _aLondon, Cheryl A | |
| 700 | 1 | _aDirikolu, Levent | |
| 700 | 1 | _aHergenrother, Paul J | |
| 700 | 1 | _aFan, Timothy M | |
| 773 | 0 |
_tInvestigational new drugs _gvol. 35 _gno. 2 _gp. 134-144 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s10637-016-0414-z _zAvailable from publisher's website |
| 999 |
_c26698445 _d26698445 |
||